Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki; Elias J. Jabbour; Farhad Ravandi; Nicholas J. Short; Deborah A. Thomas; Guillermo Garcia-Manero; Naval G. Daver; Tapan M. Kadia; Marina Y. Konopleva; Nitin Jain; Ghayas C. Issa; Vicki Jeanis; Haim G. Moore; Rebecca S. Garris; Naveen Pemmaraju; Jorge E. Cortes; Susan M. O'Brien; Hagop M. Kantarjian

doi:10.1002/cncr.30231

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

Cancer ◽

10.1002/cncr.30231 ◽

2016 ◽

Vol 122 (23) ◽

pp. 3650-3656 ◽

Cited By ~ 75

Author(s):

Koji Sasaki ◽

Elias J. Jabbour ◽

Farhad Ravandi ◽

Nicholas J. Short ◽

Deborah A. Thomas ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Propensity Score ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Score Analysis ◽

Frontline Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.7025 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 7025-7025 ◽

Cited By ~ 1

Author(s):

Koji Sasaki ◽

Hagop M. Kantarjian ◽

Farhad Ravandi ◽

Deborah A. Thomas ◽

Naval Guastad Daver ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Propensity Score ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Score Analysis ◽

Frontline Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis

Cancer ◽

10.1002/cncr.33655 ◽

2021 ◽

Author(s):

Koji Sasaki ◽

Hagop M. Kantarjian ◽

Kiyomi Morita ◽

Nicholas J. Short ◽

Marina Konopleva ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Propensity Score ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Score Analysis ◽

Frontline Therapy

Download Full-text

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

Cancer ◽

10.1002/cncr.32139 ◽

2019 ◽

Cited By ~ 9

Author(s):

Elias J. Jabbour ◽

Koji Sasaki ◽

Farhad Ravandi ◽

Nicholas J. Short ◽

Guillermo Garcia‐Manero ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Older Patients ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Intensive Chemotherapy ◽

Inotuzumab Ozogamicin ◽

Low Intensity ◽

Score Analysis ◽

Frontline Therapy

Download Full-text

When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia

Cancer ◽

10.1002/cncr.32565 ◽

2019 ◽

Vol 126 (2) ◽

pp. 253-255

Author(s):

Ryan D. Cassaday

Keyword(s):

Randomized Controlled Trial ◽

Acute Lymphoblastic Leukemia ◽

Propensity Score ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Controlled Trial ◽

Philadelphia Chromosome ◽

Randomized Controlled ◽

Score Analysis ◽

Cell Acute Lymphoblastic Leukemia

Download Full-text

Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2016.07.016 ◽

2016 ◽

Vol 16 ◽

pp. S9-S10

Author(s):

Koji Sasaki ◽

Elias Jabbour ◽

Farhad Ravandi ◽

Nicholas Short ◽

Rita Khouri ◽

...

Keyword(s):

Propensity Score ◽

Propensity Score Analysis ◽

Philadelphia Chromosome ◽

Score Analysis ◽

Philadelphia Chromosome Positive

Download Full-text

Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.07.013 ◽

2015 ◽

Vol 15 ◽

pp. S5

Author(s):

Koji Sasaki ◽

Susan O’Brien ◽

Farhad Ravandi ◽

Deborah Thomas ◽

Haim G. Moore ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Phase Ii ◽

Phase Ii Study ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Frontline Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.021 ◽

2017 ◽

Vol 17 ◽

pp. S257-S258

Author(s):

Abhishek Maiti ◽

Hagop Kantarjian ◽

Farhad Ravandi ◽

Nicholas Short ◽

Naval Daver ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Phase Ii ◽

Phase Ii Trial ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Frontline Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.07.016 ◽

2019 ◽

Vol 19 ◽

pp. S181

Author(s):

Koji Sasaki ◽

Hagop Kantarjian ◽

Guillaume Richard-Carpentier ◽

Nicholas Short ◽

Farhad Ravandi ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Older Patients ◽

Propensity Score Analysis ◽

Lymphoblastic Leukemia ◽

Intensive Therapy ◽

Philadelphia Chromosome ◽

Newly Diagnosed ◽

Inotuzumab Ozogamicin ◽

Low Intensity ◽

Score Analysis

Download Full-text

Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.7036 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 7036-7036 ◽

Cited By ~ 3

Author(s):

Koji Sasaki ◽

Hagop M. Kantarjian ◽

Farhad Ravandi ◽

Deborah A. Thomas ◽

Jorge E. Cortes ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Phase Ii ◽

Phase Ii Study ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Frontline Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718266974.793496733 ◽

2014 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Minimal Residual Disease ◽

Kinase Inhibitors ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Minimal Residual ◽

Philadelphia Chromosome Positive

Download Full-text